Capricor's Deramiocel Shows 76% Slowing of Upper Limb Decline in DMD…

Event summary

24-month HOPE-3 open-label extension data shows Deramiocel slowed upper limb decline by 76% in DMD patients who switched from placebo.
Both treatment groups exhibited slower decline than natural history predictions at 24 months.
Data included in Deramiocel BLA major amendment; PDUFA target action date set for November 22, 2026.
Webinar scheduled for October 7, 2026, to discuss results with Parent Project Muscular Dystrophy.

The big picture

Capricor's positive HOPE-3 extension data positions Deramiocel as a potential game-changer for upper limb function in non-ambulant DMD patients, a critical unmet need. The results align with broader industry trends toward cell and exosome-based therapies for rare diseases, where regulatory pathways and commercialization strategies remain challenging. The upcoming FDA decision will be a key inflection point for Capricor's valuation and strategic positioning in the muscular dystrophy treatment landscape.

What we're watching

Regulatory Approval: Whether the FDA will approve Deramiocel by the November 22, 2026 PDUFA date based on the open-label extension data.
Clinical Efficacy: How sustained the treatment effect will be beyond the 24-month mark in ongoing and future studies.
Market Potential: The pace at which Capricor can commercialize Deramiocel if approved, given the limited treatment options for non-ambulant DMD patients.